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A B S T R A C T
This paper comments on the report by a committee of La Socie´te´ Franc¸aise de Me´decine Physique et de
Re´adaptation (SOFMER) in response to the Haute Autorite´ de sante´ in France concerning the
classiﬁcation and clinical management of disorders of comportment following moderate to severe
traumatic brain injury (TBI). In view of the large number of patients and families affected by these
disorders, there is a strong rationale for these guidelines to ensure that clinical assessment and
treatment is evidence-based. The report is viewed from the perspective of current research on disorders
of comportment and in relation to recent reviews and meta-analyses on this topic. Comments on the
classiﬁcation draw on pathophysiology and brain imaging in addition to the clinical literature. The
SOFMER report and recent projects in North America are compared for trends in the development of
recommended assessment scales and standard, evidence-based treatment protocols for pharmacologic
and non-pharmacologic interventions. Collaborative, multinational investigations of TBI are also noted,
which are advancing progress toward guidelines for clinical management.




A report prepared by La Socie´te´ Franc¸aise de Me´decine Physique
et de Re´adaptation (SOFMER) in response to the Haute Autorite´ de
sante´ in France provides clinicians and researchers with accessible,
up-to-date, evidenced-based guidelines on the classiﬁcation and
clinical management of neurobehavioral disorders following
severe traumatic brain injury (TBI). This consensus document
synthesizes contributions by a multidisciplinary committee
representing clinicians and investigators. Through their delibera-
tions, this committee of TBI specialists achieved a common ground
on the classiﬁcation and clinical management of neurobehavioral
sequelae (i.e., disorders of comportment during the post-acute and
chronic stages of severe TBI). In this scholarly report, the
committee has provided readers with clear deﬁnitions of the
disorders.
Although a comparable document on this topic has not, to my
knowledge, been disseminated in North America, the Brain Injury
Association of America in association with Mount Sinai Medical
Center in New York has initiated the project ‘‘Guidelines for the
Rehabilitation and Chronic Disease Management of Adults with
Moderate to Severe TBI’’. This project is currently compiling* Tel.: +7137987566; fax: +7137987259.
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1877-0657/ 2015 Elsevier Masson SAS. All rights reserved.questions to be addressed by panels of rehabilitation experts
concerning issues in the behavioral, cognitive, functional, medical,
and participation/vocational domains. The project is soliciting
feedback from the rehabilitation community to revise questions
drafted in each domain and review additional questions (http://
www.biausa.org/TBIGuidelines/tbi-rehabilitation-guidelines_
feedback).
2. Recent North American projects related to the SOFMER
report
Published reviews by groups working to develop guidelines or
at least a consensus on clinical management of cognitive and
behavioral problems from TBI include the 2006 Warden et al. [1]
seminal review of pharmacologic therapy for neurobehavioral
sequelae of TBI. The authors reviewed the evidence supporting
speciﬁc drugs for treatment of poor attention and slowed
processing speed, other cognitive deﬁcits, aggression, depression,
anxiety, and other psychiatric conditions after TBI. At the time of
their review, Warden et al. [1] noted that the evidence was
especially robust for treating attentional disturbance with
methylphenidate, but they emphasized the general need for
additional randomized clinical trials (RCTs) to provide a more
evidenced-based approach to pharmacologic treatment. In con-
trast, the Frenette et al. [2] review of dopaminergic medications for
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authors noted the heterogeneity in methods across clinical trials
(e.g., different outcome measures) and were guarded concerning
whether the current evidence supported clinical guidelines for the
medications that they reviewed.
Recommendations from the recent review of pharmacologic
management of cognitive impairment by Arciniegas and Silver [3]
were similar to those by SOFMER, including caution about the use
of neuroleptics, benzodiazapine, anticonvulsants, and anticho-
linergics. Arciniegas and Silver also highlighted the evidence for
the effectiveness of amantadine in treating disorders of con-
sciousness; they advocated for non-pharmacologic interventions
such as environmental changes and cognitive training, a
perspective consistent with SOFMER. The Wheaton et al. meta-
analysis [4] focused on treating cognitive deﬁcit and supported
methylphenidate for treating attention and slowed cognitive
processing. In 2011, the US National Academy of Science
published a report by a multidisciplinary panel that evaluated
the evidence for cognitive rehabilitation of TBI patients, with an
emphasis on mild TBI [5]. The panel concluded that the evidence
provided limited support for speciﬁc interventions to treat
problems in attention, executive function, memory and commu-
nication. However, it also noted the need for clinical trials to
standardize treatments using manuals that are accessible to other
investigators, developing a common registry or linked registries of
rehabilitation outcome data to facilitate meta-analyses, and
bridging the gap between standard outcome measures and
evaluation of everyday functioning.
Guidelines for the management of sports concussion have been
published by the Fourth International Conference on Concussion in
Sport [6] and the American Academy of Neurology [7]. Protocols for
concussion management in North America are well established
and widely followed but still lack support by rigorous RCTs. The
international sports concussion literature suggests that concussion
management protocols may be less widely implemented in Europe
than in North America, but I am not aware of any surveys of
trainers and physicians to compare practices across these
continents.
The ongoing NIH-supported TRACK-TBI project is a multina-
tional research consortium using advanced brain imaging and
longitudinal follow-up of a large cohort to study the outcomes of
TBI and the neural underpinnings of the sequelae [8]. In time, this
approach may extend to rehabilitation and hopefully address
guidelines for clinical management of post-acute and chronic,
severe TBI [9].
3. Rationale for the SOFMER report
The premise that the neurobehavioral sequelae or problems of
comportment are primary concerns for rehabilitation is supported
by studies that reported cognitive and behavioral sequelae as the
most frequent basis for disability at 6 months in two thirds of
patients with severe TBI [10]. Similarly, interviews and rating
scales given to families have documented that their concerns and
burdens as caregivers focused more on behavioral issues than
cognitive impairment and physical disability [11].
4. Classiﬁcation of neurobehavioral disorders
In general, the classiﬁcation of 4 types of neurobehavioral
disorders agrees with clinical neuroscience research on post-acute
and chronic stages of severe TBI. Disorders of excess behaviour
(e.g., disinhibition, irritability, and aggression) and deﬁcient
behaviour such as apathy and depression involve distinct brain
regions (e.g., orbitofrontal for disorders of excess) or systems(orbitofrontal-amygdala) and imbalance of neurotransmitters
(e.g., dopaminergic for attention) or hormones. Identifying focal
lesions in regions associated with disorders of comportment is
informative clinically. However, functional imaging has disclosed
that disruption of connectivity of key networks is an important
mechanism in these conditions independent of focal lesions. For
example, functional brain imaging studies [12] have implicated
prefrontal-amygdala connections in emotional and behavioral
regulation and their vulnerability to severe closed head trauma.
Orbitofrontal and inferior frontal regions have been implicated in
the capacity to inhibit inappropriate or irrelevant responses to
situations [13]; reduced modulation of the amygdala by prefrontal
cortex is also implicated in emotional memory and post-traumatic
stress disorder [14].
The recognition of apathy and reduced motivation in the
classiﬁcation of disorders of comportment is consistent with the
extensive literature documenting the high frequency of these
problems following severe TBI. The document also presents a
strong case for differentiating apathy from depression.
Disorders classiﬁed by the committee as ‘‘secondary’’ such as
depression and anxiety are frequent after TBI and represent
challenges to rehabilitation. The status of depression as a direct
effect of TBI or in reaction to the resulting deﬁcits and disability is
not entirely clear. The independent status of suicide as a separate
category can be questioned because it is a complex action that
involves mechanisms in the disorders classiﬁed in categories I–III.
Could suicide have been included in depression and perhaps
agitation or aggression?
The SOFMER committee recognized that disorders of
comportment are often chronic effects of severe TBI. Advances
in research have characterized diffuse axonal injury, metabolic,
and neurohormonal effects of TBI that contribute to evolving
disturbances of affect and behavior. The discovery that subclini-
cal seizures are more common than previously thought is
another mechanism contributing to the late effects of severe
TBI [15]. There is growing recognition that severe TBI triggers
cellular processes that lead to neurodegeneration involving
inclusion of hyper-phosphorylated tau and deposits of amyloid,
which increase the risk of dementia or other neurodegenerative
conditions [16]. The trajectory of age-related changes in cognition
may be accelerated even in TBI patients who appear to evade a
neurodegenerative disorder [17]. Individual differences in suscepti-
bility to the chronic effects of severe TBI is also important to
recognize. The committee addressed gender differences and alluded
to genotype, a well-established factor in the risk of Alzheimer’s
disease in this population [18]. Alterations of behavior, mood, and
cognition in the years following exposure to repetitive mild head
trauma may be a harbinger of chronic traumatic encephalopathy
[19]. Epidemiological evidence suggests that a single moderate to
severe TBI increases the risk of dementia in people  55 years old
[20].
5. Moderators of disorders of comportment
The SOFMER committee identiﬁed factors that increase the risk
of disorders of comportment and alluded to factors that are
protective. These ‘‘moderators’’ include genotype (e.g., APOE allele
[18]), gender, education, and socioeconomic status. APOE 4 carriers
are more vulnerable to poor outcomes after severe TBI, whereas
education and an advantaged environment can be considered
proxies for cognitive reserve [21] (i.e., the capacity to withstand or
resist the adverse effects of neuropathology or other brain insults
on cognitive decline) [21]. Similarly, resilience is increasingly
being recognized as protective against post-traumatic stress
disorder, depression, and other secondary effects of TBI.
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The committee appropriately addressed the need to develop a
uniform approach to assessment of disorders of comportment,
acknowledging the importance of satisfactory reliability, validity
and the availability of translations. Although a translation is
essential, the effect of cultural differences may still be an issue
depending on the population. Standardization of assessment
methods facilitates comparison across studies and eventually
meta-analysis of aggregated datasets from different studies. In
the United States, the National Institutes of Health (NIH) and other
Federal agencies have supported the development of Common Data
Elements [22] (CDEs) for assessing various domains of outcomes,
including cognition, behavior, and participation. CDEs are also
available to document acute TBI characteristics, structural imaging
results, treatment, and complications. Growing recognition that
diagnostic assessment and evaluation of outcomes should include
patient-reported outcomes has led to NIH-supported development
of measures such as the Neuro-QoL [23], which consists of 13 item
banks from which Cella et al. extracted short forms of 8 or 9 items.
The Neuro-QoL includes measures that assess everyday functioning,
social participation, applied cognition (e.g., everyday memory),
behavior, and psychological health (e.g., depression) from the
patient perspective. This approach, including use of item response
theory, is consistent with the multi-level assessment proposed by
the SOMER committee. The CDEs and Neuro-QoL short forms can be
found on the website for the US National Institute of Neurological
Disorders and Stroke (http://www.ninds.nih.gov/research/
clinical_research/toolkit/common_data_elements.htm).
7. Medical, family, and social perspectives on treatment
The SOFMER report’s recommendations for clinical manage-
ment of severe TBI include the individual, family, and social
dimensions of rehabilitation in addition to the neurobiological and
medical issues. This broad approach is also compatible with the
World Health Organization Model of Disability and Participation,
widely accepted by clinicians involved in rehabilitation. Emphasis
on the environment, as espoused in the report, is in-line with
current approaches that consider patients in their environment
when planning treatment. As noted in the report, understanding
the patient’s environment can also facilitate behavioral inter-
ventions or rearrangement of the environment to reduce behaviors
such as agitation and aggression.
8. Differences in clinical management between France and the
United States
The sections of the SOFMER report on treatment of the post-
acute and chronic behavioral disorders of comportment are up-to-
date and acknowledge differences in current practice between
Europe and North America. For example, cognitive behavioral
therapy is widely used in the United States but possibly
underutilized in France. The report presents a modern approach
to medication management for behavioural sequelae of severe TBI
that is similar to current practice in the United States as described
in the recent reviews cited above. The ﬁrst-line medications
proposed mitigate extrapyramidal effects and minimize interfer-
ence with neuroplasticity. As noted in the report, in some crises,
short-term use of neuroleptics might be necessary, which is
consistent with practice in the United States.
9. Summary
The report prepared by the SOFMER committee synthesizes
evidence-based classiﬁcation of disorders of comportment resultingfrom moderate to severe TBI and provides guidelines for treatment
in a rehabilitation setting. It will inform clinicians and researchers on
the current approach to treating cognitive and behavioral sequelae
of moderate to severe TBI. Despite the advances in assessment and
treatment presented in this report, the authors have appropriately
noted gaps in knowledge that dictate a cautious approach to
treatment. International collaboration is contributing to standardi-
zation of evidenced-based clinical management of TBI patients, but
distinct aspects of assessment and treatment in Europe and North
America are well described in this report.
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